Hormonal IUD (Mirena/Kyleena) and Trazodone Interaction: What Women Need to Know

Is There a Real Drug Interaction Between a Hormonal IUD and Trazodone?

The short answer is: not a clinically significant pharmacokinetic one. Trazodone and levonorgestrel do not share a metabolic pathway in a way that would lower the progestin concentration at the endometrium where it does its work. The interaction that does exist is pharmacodynamic: both drugs can cause sedation, and women who take trazodone for sleep or depression while using the IUD for mood-adjacent hormonal symptoms may notice additive central nervous system (CNS) effects.

This distinction matters. A pharmacokinetic interaction could theoretically make your IUD fail. A pharmacodynamic interaction affects how you feel day-to-day. Understanding which category applies here helps you and your clinician make an informed decision rather than an unnecessarily anxious one.

How Levonorgestrel Works in the IUD

The Mirena 52 mg levonorgestrel IUD releases approximately 20 mcg of levonorgestrel per day initially, dropping to roughly 10 mcg/day after five years. Kyleena (19.5 mg) releases about 17.5 mcg/day at placement. The mechanism of action is primarily local: progestin thickens cervical mucus, suppresses endometrial proliferation, and in some women (though not reliably) may inhibit ovulation. Because the hormone acts almost entirely at the uterine level, systemic blood concentrations are far lower than oral or injectable progestins, which is exactly why drug interactions that affect systemic progestin metabolism are far less relevant here than they would be with a pill.

How Trazodone Works

Trazodone is a serotonin antagonist and reuptake inhibitor (SARI). It blocks serotonin 5-HT2A and 5-HT2C receptors, weakly inhibits serotonin reuptake, and has significant histamine H1 and alpha-1 adrenergic antagonism. That last property is why it causes sedation at lower doses (25 to 100 mg), which is the dose range most women use it for sleep. At antidepressant doses (150 to 400 mg), the serotonergic effects become more prominent.

Trazodone is metabolized primarily by CYP3A4, producing an active metabolite called meta-chlorophenylpiperazine (mCPP). Levonorgestrel is also metabolized partly by CYP3A4 when it enters systemic circulation. Here is where the interaction question gets interesting.

The CYP3A4 Question: Does Trazodone Affect Levonorgestrel Levels?

This is the mechanism women and clinicians worry about most. If trazodone inhibited CYP3A4 strongly, it could theoretically raise systemic levonorgestrel. If it induced CYP3A4, it could lower levonorgestrel. Neither scenario is likely to matter much for an IUD, but let's be precise.

Trazodone's Effect on CYP3A4

Trazodone is a weak CYP3A4 inhibitor at therapeutic doses. It does not induce CYP3A4. Drugs that cause clinically meaningful reductions in oral contraceptive efficacy (rifampin, carbamazepine, phenytoin, topiramate above 200 mg/day) are strong CYP3A4 inducers. Trazodone is not in that category.

More to the point: even if trazodone mildly inhibited CYP3A4 and slightly raised systemic levonorgestrel, that would not reduce contraceptive effectiveness. It might theoretically increase systemic progestin side effects (bloating, mood changes), but the primary contraceptive action of the IUD is local and would be unaffected or even marginally strengthened.

Why the IUD Is Unusually Resistant to Drug Interactions

ACOG Practice Bulletin No. 186 on long-acting reversible contraception makes a point that many women's prescribers miss: intrauterine devices, both copper and hormonal, have no meaningful drug interactions that reduce their effectiveness. The physical presence of the device in the uterus and the local progestin effect on cervical mucus are not dependent on serum drug concentrations in the way that oral contraceptives are. Enzyme inducers that reliably reduce pill efficacy do not reduce IUD efficacy by any clinically significant margin.

This is a meaningful distinction if you are a woman managing epilepsy, tuberculosis, or another condition requiring CYP-inducing medications. Your IUD is your safest hormonal option precisely because it bypasses the gut and the liver.

Pharmacodynamic Interaction: The Sedation and Mood Overlap

The interaction that actually affects women's daily experience is pharmacodynamic. Both trazodone and levonorgestrel can influence mood and CNS function, though through very different mechanisms.

Sedation Overlap

Trazodone causes dose-dependent sedation. So does levonorgestrel in some women, though the evidence for IUD-level systemic progestin causing sedation is weak because serum levels are so low. Still, women who are sensitive to progestin effects may notice fatigue or low mood when first placed with a hormonal IUD. If you are already taking trazodone nightly for sleep, that fatigue can feel amplified in the first few weeks post-insertion.

The practical guidance: time your IUD insertion for a period when you can rest for 24 to 48 hours if needed, and give your body four to six weeks before concluding that trazodone-plus-IUD is causing intolerable fatigue.

Mood and the Progestin-Serotonin Connection

Here is a framework not widely discussed in standard drug-interaction resources: levonorgestrel, even at IUD-level systemic concentrations, has demonstrated activity at GABA-A receptors via neurosteroid pathways, similar in type (though much smaller in magnitude) to the neurosteroid effects seen with high-dose oral progestins. Trazodone's 5-HT2C antagonism increases dopamine and norepinephrine release in the prefrontal cortex. In a woman with premenstrual dysphoric disorder (PMDD) or perimenopausal mood instability who is using the IUD partly for hormonal cycle suppression, trazodone's serotonergic and the IUD's GABAergic effects may compound, for better or worse depending on the individual. This does not rise to a formal drug-drug interaction, but it is a clinical signal worth discussing with your prescriber if you experience unexpected mood changes after starting either drug while already on the other.

No published trial has directly studied trazodone plus levonorgestrel IUD in women with PMDD or perimenopausal depression. This is an evidence gap. Any clinical guidance here is extrapolated from the individual drug mechanisms, not from co-administration data.

Life-Stage Considerations

Reproductive Years (Ages 18 to 40)

For most women in their reproductive years using a hormonal IUD for contraception or heavy menstrual bleeding (HMB), trazodone co-administration carries no contraceptive concern. Sleep difficulties are common in women with HMB-related iron-deficiency anemia, and trazodone is sometimes prescribed in this context. Your IUD efficacy is not at risk.

If you are using trazodone for depression, discuss with your prescriber whether the IUD's low-level progestin might interact with your mood response. A 2023 cohort study in JAMA Psychiatry found that adolescent and young adult women using hormonal contraception had modestly higher rates of depression diagnosis than non-users, though this association was smaller for IUD users than for combined oral contraceptive users, likely because of the lower systemic hormone exposure.

Trying to Conceive

If you are planning to remove your IUD to try to conceive, you should discuss whether trazodone is safe to continue during pregnancy before the IUD is removed, not after you discover a pregnancy.

Perimenopause (Ages 40 to 55)

This is the life stage where co-prescription of trazodone and a hormonal IUD is most common. Trazodone is frequently used off-label for perimenopausal sleep disruption, at doses of 25 to 100 mg at bedtime. The 52 mg Mirena IUD is used in this group for HMB (fibroids and adenomyosis become more prevalent), for endometrial protection when estrogen therapy is added for vasomotor symptoms, and occasionally for dysmenorrhea.

Women in perimenopause should be aware of two things. First, the sedation from trazodone may feel more pronounced if declining estrogen is already affecting sleep architecture and daytime energy. Second, if you are also on systemic estrogen therapy (oral, patch, or gel), the estrogen is also partially metabolized by CYP3A4, and trazodone's weak CYP3A4 inhibition could mildly raise estrogen levels. This is unlikely to be clinically significant at typical trazodone doses but worth mentioning to your menopause specialist.

Post-Menopause

The Mirena IUD is used off-label in post-menopausal women as the progestogen component of menopausal hormone therapy (MHT). The British Menopause Society has published data supporting this use, though it remains off-label in the United States. Trazodone for sleep or depression in this group is common. The interaction profile remains the same: no pharmacokinetic concern, possible additive sedation.

Conditions This Interaction Touches

Several female-specific conditions place women at the intersection of IUD use and trazodone use. Recognizing them helps you see whether this combination applies to your situation.

Endometriosis. The levonorgestrel IUD reduces endometriosis-associated pain in many women. Chronic pain is strongly associated with depression and sleep disturbance, making trazodone co-prescription plausible. No interaction concern exists.

PCOS. Women with polycystic ovary syndrome often use the IUD for endometrial protection (the IUD thins the endometrium and reduces risk of hyperplasia from chronic anovulation). Depression and anxiety rates are elevated in PCOS. Trazodone may be used for sleep. Again, no pharmacokinetic interaction.

Fibroids and adenomyosis. These are primary indications for the Mirena IUD in women aged 35 to 55. Chronic heavy bleeding causes fatigue and disrupted sleep, making trazodone co-prescription common in this group.

PMDD. Trazodone is not a first-line treatment for PMDD (SSRIs are), but it is sometimes used adjunctively for the sleep component of PMDD. The IUD may reduce the hormonal cycling that drives PMDD. The interaction here is more complex (see the mood framework above) and warrants conversation with your prescriber.

Pregnancy, Lactation, and Contraception

If the IUD is in place, pregnancy is extremely unlikely. The typical-use failure rate for the 52 mg Mirena is 0.1 to 0.8% per year, making it one of the most effective reversible contraceptives available. Trazodone does not increase that failure rate.

If pregnancy does occur while you are taking trazodone with an IUD in place, this is a medical urgency. Intrauterine pregnancy with an IUD in place carries increased risk of ectopic pregnancy and second-trimester loss. The IUD should be removed as early in pregnancy as safely possible. And trazodone's safety profile in pregnancy becomes immediately relevant.

Trazodone in pregnancy. Trazodone carries FDA Pregnancy Category C, meaning animal studies showed adverse fetal effects and adequate human studies are lacking. The available human case series and registry data do not show a consistent teratogenic signal for trazodone, but the data are limited. A 2016 analysis in BMJ Open found no statistically significant increase in major malformations with first-trimester trazodone exposure, though the confidence intervals were wide. If you discover you are pregnant while taking trazodone, do not stop abruptly without speaking to your prescriber. Abrupt discontinuation of antidepressants in pregnancy carries its own risks.

Trazodone in lactation. Trazodone transfers into breast milk at low levels. A pharmacokinetic study published in the British Journal of Clinical Pharmacology found a milk-to-plasma ratio of approximately 0.142, suggesting minimal infant exposure. LactMed (NLM) classifies trazodone as likely compatible with breastfeeding, though routine monitoring of the infant for sedation is advised. If you are postpartum and considering resuming trazodone while breastfeeding and while your new hormonal IUD is being placed (typically at the six-week visit), discuss timing with your OB or midwife.

Contraception requirement. Because the IUD is itself a contraceptive, no additional contraception is needed for trazodone. Trazodone is not a teratogen in the category that requires mandatory contraception (unlike isotretinoin or methotrexate), but given its Category C status, women of reproductive age who are not using the IUD and who are sexually active should use reliable contraception while taking trazodone.

Monitoring and Practical Guidance

Women taking trazodone alongside a levonorgestrel IUD do not need extra laboratory monitoring for the interaction itself. The clinical checklist is:

• Sedation assessment. At your first follow-up after starting trazodone (or after IUD insertion if trazodone was already on board), report excessive daytime sleepiness, dizziness, or falls. Dose timing (trazodone taken 30 to 60 minutes before bed) minimizes next-day sedation.
• Mood tracking. If you use the IUD partly for cycle-related mood symptoms, note whether trazodone improves or paradoxically worsens mood. The mCPP metabolite of trazodone can provoke anxiety or dysphoria in some women, a known trazodone-specific side effect unrelated to the IUD.
• No dose adjustment is needed for either drug based on this combination.
• IUD string check. Standard post-insertion string check at four to six weeks applies regardless of trazodone use.
• Driving and machinery. If you are taking trazodone at sedating doses and have just had an IUD inserted (post-insertion cramping may itself be fatiguing), arrange a ride home from your appointment.

Who This Combination Is Right For, and Who Should Think Twice

Good candidates for both

• Women in perimenopause with HMB and sleep disruption who want IUD-based endometrial protection and low-dose trazodone for sleep
• Women with endometriosis-associated pain and comorbid depression or insomnia
• Women with PCOS who need endometrial protection and have sleep difficulties
• Women who have tried first-line SSRIs and prefer trazodone's side-effect profile

Women who need a closer conversation

• Women with PMDD who are using both for mood-related indications. The interaction of progestin neurosteroid effects and trazodone's serotonergic effects is not well-studied and warrants shared decision-making.
• Women who metabolize trazodone slowly (CYP2D6 poor metabolizers). These women accumulate higher levels of trazodone's anxiogenic mCPP metabolite, which can worsen mood. This is a trazodone-specific concern, not an IUD-specific one, but it may be unmasked if mood was previously attributed to hormonal causes.
• Women in perimenopause also taking systemic estrogen therapy. Discuss the mild CYP3A4 inhibition by trazodone with your menopause clinician, particularly if you are on oral estradiol (higher first-pass metabolism than patches).
• Women with a history of orthostatic hypotension. Trazodone's alpha-1 blockade plus the post-insertion vasovagal response that some women experience with IUD placement can compound dizziness. IUD insertion should ideally be timed away from trazodone peak plasma levels (roughly one to two hours post-dose).

What the Evidence Actually Shows (and Where the Gaps Are)

No published clinical trial has directly studied the trazodone plus levonorgestrel IUD combination. This is an honest statement of the evidence gap. The reassurance that this combination is safe comes from:

1. The pharmacokinetic reasoning that trazodone does not meaningfully induce CYP3A4, and that even strong CYP3A4 inducers do not reduce IUD efficacy per ACOG's LARC guidance.

2. The low systemic levonorgestrel exposure from the IUD, which reduces the relevance of any metabolic interaction.

3. The absence of any signal in pharmacovigilance databases (FDA FAERS) or published case reports linking trazodone to IUD failure or levonorgestrel toxicity.

4. Individual drug safety data that, when considered together, do not suggest a synergistic harm.

Women deserve to know when reassurance is based on mechanistic reasoning rather than direct clinical trial data. Here it is: the confidence is mechanistic. That is still a sound basis for clinical practice, but it is not the same as a well-powered randomized trial, and you should factor that into your own decision-making.